Skip to content

Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice

An Open Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00301340
Enrollment
200
Registered
2006-03-10
Start date
2006-03-31
Completion date
Unknown
Last updated
2007-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head Lice

Brief summary

Summers Laboratories has developed a non-pesticide treatment for head lice. Lice Asphyxiator (L.A.) works by mechanically blocking the respiratory spiracles of the head lice, therefore causing a quick-acting suffocation that will not result in the development of resistance. The objectives of this open label study are to evaluate the efficacy and safety of home use of two 10-minute treatments of 5% L.A. (applied one week apart).

Interventions

DRUG5% Lice Asphyxiator lotion - Summers Laboratories, Inc.

Sponsors

Summers Laboratories
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No

Inclusion criteria

1. Males and females 6 months of age or older. 2. Have an active infestation with Pediculus capitis, the human head louse, with at least three live lice at baseline, or treatment failure with any live lice from Protocol SU-01-2005 or Protocol SU-02-2005. 3. Agree not to use any other pediculicides or medicated hair grooming products during the duration of the study. 4. Be healthy, non-febrile, and not suffering from an infection likely to require antibiotic therapy during the study period. 5. Subject or guardian is able to understand the new HIPAA regulations and sign the HIPAA form. 6. Subject or guardian has read, understood, and signed appropriate informed consent in English. If English is not the primary language, the information about the study must be explained in their language and a copy of the informed consent must be in that language. 7. Subject is willing to participate in the study, and abide by the protocol requirements. \-

Exclusion criteria

1. Participation in any clinical study, excluding protocols SU-01-2005 and SU-02-2005, within the past 30 days. 2. Known hypersensitivity to any ingredient in the product formulation.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026